The document discusses engineering human skeletal muscle tissue for developing therapies for muscle injuries and evaluating medicines. It outlines several cell types and biomaterials that can be used, including satellite cells, myoblasts, stem cells, and natural or synthetic polymers. Novel techniques like 3D bioprinting, organ-on-chip models, and combining cell sources, scaffolds, and stimuli seek to better recreate muscle tissue functionality in vitro and in vivo. Current challenges include scaling up engineered tissues for transplantation, but emerging technologies may help address limitations and reduce animal testing.